Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.
Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.
Ophthalmol Retina. 2021 Aug;5(8):788-796. doi: 10.1016/j.oret.2020.11.008. Epub 2020 Nov 20.
Topical povidone-iodine (PI) is widely used as an ocular surface antiseptic for intravitreal injections (IVIs). Although PI is generally well tolerated, it can be associated with significant ocular irritation. Aqueous chlorhexidine (AqCHX) has been described as a possibly better tolerated antimicrobial for ophthalmic procedures. We compared patient pain scores, ocular surface characteristics, and antimicrobial efficacy between PI 5% and AqCHX 0.1% during IVIs.
Prospective single-center, randomized clinical trial.
Patients receiving same-day bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injections.
Each patient had 1 eye randomized to PI or AqCHX, and the second eye received the other agent. Both eyes received topical proparacaine 0.5%.
After IVIs, participants rated their pain (Wong-Baker, scale 0-10) for each eye 1 minute after PI or AqCHX instillation and 1 day after the procedure. Each eye was assessed using a standardized quantitative grading system of corneal epitheliopathy (ocular staining score). Microbial swab cultures of the conjunctiva both before instillation of topical antisepsis and 10 minutes after IVIs were given.
A total of 100 eyes of 50 patients were included. The mean patient age was 68 years (range, 39-92), and 30 of 50 (60%) were male. Compared with AqCHX, eyes receiving PI had a greater mean pain score immediately after injection (1.44 vs. 0.44, P < 0.001) but not on postprocedure day 1 (1.04 vs. 0.48, P = 0.06). Eyes that received PI had a higher ocular staining score indicating worse corneal epitheliopathy (4.22 vs. 3.10, P < 0.001). There was no difference in rates of positive microbial cultures between groups. There was no difference in rates of adverse events between groups (P = 0.99), and no cases of endophthalmitis occurred.
Povidone-iodine demonstrated greater ocular surface discomfort and corneal epitheliopathy compared with AqCHX during same-day bilateral IVIs. The 2 agents otherwise demonstrated no difference in positive microbial cultures or adverse events. Aqueous chlorhexidine may be a better tolerated alternative to PI for antimicrobial prophylaxis during IVIs for some patients.
局部聚维酮碘(PI)广泛用作玻璃体腔内注射(IVI)的眼表防腐剂。尽管 PI 通常具有良好的耐受性,但它可能与明显的眼部刺激有关。洗必泰已被描述为一种可能更耐受眼科手术的抗菌剂。我们比较了 PI 5%和 AqCHX 0.1%在 IVI 期间的患者疼痛评分、眼表特征和抗菌效果。
前瞻性单中心随机临床试验。
接受同日双侧玻璃体腔内抗血管内皮生长因子(VEGF)注射的患者。
每位患者的 1 只眼随机接受 PI 或 AqCHX 治疗,另 1 只眼接受另一种药物治疗。两只眼睛均接受局部丙卡因 0.5%滴眼。
IVI 后,参与者在 PI 或 AqCHX 滴注后 1 分钟和术后 1 天,对每只眼的疼痛(Wong-Baker,0-10 级)进行评分。使用角膜上皮病变的标准化定量分级系统(眼染色评分)评估每只眼。在局部消毒前和 IVI 后 10 分钟对结膜进行微生物拭子培养。
共纳入 50 例患者的 100 只眼。患者平均年龄为 68 岁(范围,39-92 岁),其中 30 例(60%)为男性。与 AqCHX 相比,接受 PI 的眼睛在注射后即刻的平均疼痛评分更高(1.44 比 0.44,P<0.001),但在术后第 1 天(1.04 比 0.48,P=0.06)无差异。接受 PI 的眼睛的眼染色评分更高,表明角膜上皮病变更严重(4.22 比 3.10,P<0.001)。两组之间的微生物培养阳性率无差异。两组之间的不良事件发生率无差异(P=0.99),也没有发生眼内炎。
与 AqCHX 相比,PI 在同日双侧 IVI 期间引起更大的眼表不适和角膜上皮病变。两种药物在微生物培养阳性率或不良事件方面没有差异。对于某些患者,洗必泰可能是 PI 用于 IVI 时抗菌预防的更耐受替代药物。